MYL News and Press, Mylan N.V. From 03/20/20

Despite what President Donald Trump said at a White House briefing on Thursday, the Food and Drug Administration (FDA) hasn't approved chloroquine and its less-potent-but-safer offspring, hydrochloroquine, to treat COVID-19 , the disease caused by the new coronavirus. "Normally the FDA would t...

Teva Pharmaceutical (NYSE: TEVA) plans to donate 10 million tablets of the malaria drug hydroxychloroquine sulfate as a potential treatment for COVID-19 . That news follows a report from earlier this week that Bayer (OTC: BAYRY) plans to donate 3 million tablets of the related drug chl...

Along with taking a huge toll in terms of human suffering and death, and upending everyday life, the novel coronavirus pandemic has caused extreme turbulence in the stock market. Investors are naturally concerned about the magnitude of the economic fallout from the crisis. Last week, all t...

While high-momentum stocks have completely dominated cheaper value stocks over the past decade since the 2008 global financial crisis, recent events have turned the tables in a big way. There's no better example than the success of recent stock picks by  Berkshire Hathaway (NYSE: BRK.A) ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Big gains were seen across every asset class overnight as policymakers pulled out all the stops and adopted a "whatever it takes" app...

Mylan (NASDAQ: MYL) has restarted production of its hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility as a potential treatment for COVID-19 , the disease caused by the new coronavirus. The company plans to have product available by mid-April and thinks it can ra...

Mylan N.V. ( MYL +6% ) has restarted production of hydroxychloroquine sulfate tablets at its West Virginia facility in order to meet COVID-19-related demand, although it is not formerly approved for this use (currently authorized to treat malaria, lupus erythematosus and rheumatoid arthr...

HERTFORDSHIRE , England and PITTSBURGH, March 19, 2020 /PRNewswire/ --  Mylan N.V.  (NASDAQ: MYL) today announced its continued commitment to do its part in support of public health needs amidst the evolving COVID-19 pandemic. The company continues to focus its efforts...

March 16, 2020 Palm Beach, FL – March 16, 2020 – The U.S. and other countries worldwide are sharing information and mobilizing to collectively corral the coronavirus pandemic with all due speed. As a result, a new and private/public collaboration has been formed and it i...

Choosing between biotech giants Biogen (NASDAQ: BIIB) and Amgen (NASDAQ: AMGN) is not an easy task. Both companies have attractive pipelines and solid suites of products on the market. Though Amgen's revenue declined in 2019 while Biogen's rose, Amgen offered a better revenue outloo...